Xanthine oxidoreductase activity in platelet-poor and rich plasma as a oxidative stress indicator in patients required renal replacement therapy

• DOI: 10.1186/s12882-021-02649-8
• Publication Date: 2022-01-18T09:22:59Z
• Authors: Elżbieta Cecerska...; Rafał Heryć; Grażyna Dutkiewicz; Anna Michalczyk; Bartłomiej Grygor...; Natalia Serwin; Sylwia Napiontek-...; Barbara Dołęgowska
• Keywords: Nephrology; Malondialdehyde; Xanthine

Xanthine oxidoreductase (XOR) is a hydroxylase enzyme involved in the metabolism of purines. XOR activity can vary: homodimer protein be converted into two different isoforms XD (antioxidant) and XO (prooxidant). Oxidative stress inflammation that accompanying chronic kidney disease (CKD), dialysis, transplantation, resulted platelet activation. Present study aimed to determine influence applied renal replacement therapy on xanthine its activity.The group consisted 117 patients, divided 4 groups: hemodialysis - 30 peritoneal dialysis transplant patients 27 conservative treatment patients. The control healthy volunteers.Significant differences were found platelet-poor plasma (PPP) within groups studied (p = 0.001). There was relationship between type all PPP < 0.001 isoforms) 0.008), 0.001) rich-plasma (PRP). A observed PRP, duration age cause also reflected PPP.The used CKD causes, stage progression significantly affect isoforms.